Education
About Us
Working with TipRanks
Follow Us
AC Immune SA (ACIU)
NASDAQ:ACIU
ACIU Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.43 - $3.93
Previous CloseN/A
Volume13.14K
Average Volume (3M)124.25K
Market Cap
$250.33M
Enterprise Value$50.74M
Total Cash (Recent Filing)$127.14M
Total Debt (Recent Filing)$4.92M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 14, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding98,943,130
10 Day Avg. Volume127,956
30 Day Avg. Volume124,245
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.20
Enterprise Value/Revenue1.75
Enterprise Value/Gross Profit1.75
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$10.00Price Target Upside296.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial StabilityCash resources of CHF 127.1 million should provide cash for operations through Q3 2027 not including potential payments from partnering.
Immunotherapy DevelopmentPromising immunogenicity readouts for active immunotherapies targeting both AD and PD patients suggest less cumbersome treatment approaches than monthly mAb infusions.
Pipeline ProgressSeveral interim and initial data points from ongoing studies are expected, highlighting progress in key areas such as Parkinson’s disease and Alzheimer's disease.
Bears Say
Cash Burn ConcernsThe company ended 1Q25 with CHF 127M in cash, which should provide funding into 1Q27.
Spending ReductionsManagement indicated that it was reducing spending and increasing operational efficiency to focus on key programs focused on disease prevention that may reach important value-inflection milestones in the next 2 years.
Technical RisksThere are still technical risks to these programs as each vaccine-ish therapy makes some guesses over the structure of the toxic species to be cleared.
AC Immune SA News
ACIU FAQ
What was AC Immune SA’s price range in the past 12 months?
AC Immune SA lowest stock price was $1.43 and its highest was $3.93 in the past 12 months.
What is AC Immune SA’s market cap?
AC Immune SA’s market cap is $250.33M.
When is AC Immune SA’s upcoming earnings report date?
AC Immune SA’s upcoming earnings report date is Nov 14, 2025 which is in 49 days.
How were AC Immune SA’s earnings last quarter?
AC Immune SA released its earnings results on Aug 05, 2025. The company reported -$0.26 earnings per share for the quarter, the consensus estimate of -$0.26 by $0.
Is AC Immune SA overvalued?
According to Wall Street analysts AC Immune SA’s price is currently Undervalued.
Does AC Immune SA pay dividends?
AC Immune SA does not currently pay dividends.
What is AC Immune SA’s EPS estimate?
AC Immune SA’s EPS estimate is -0.24.
How many shares outstanding does AC Immune SA have?
AC Immune SA has 98,943,130 shares outstanding.
What happened to AC Immune SA’s price movement after its last earnings report?
AC Immune SA reported an EPS of -$0.26 in its last earnings report, expectations of -$0.26. Following the earnings report the stock price went up 11.364%.
Which hedge fund is a major shareholder of AC Immune SA?
Currently, no hedge funds are holding shares in ACIU
AC Immune SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (296.83% Upside)
$10.00 (296.83% Upside)
Blogger Sentiment
Bullish
ACIU Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 739.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.14%
12-Months-Change
Fundamentals
Return on Equity
-50.57%
Trailing 12-Months
Asset Growth
-9.60%
Trailing 12-Months
Company Description
AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
ACIU Stock 12 Month Forecast
Average Price Target
$10.00
▲(296.83% Upside)
Technical Analysis
Sangamo Biosciences
―
Innate Pharma
―
Inhibikase Therapeutics
―
Nanobiotix
―
Molecular Partners
―
Ownership Overview
―
Insiders
0.19% Mutual Funds
20.24% Other Institutional Investors
79.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---